1 – 10 of 33
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
(
- Contribution to journal › Article
- 2019
-
Mark
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities : further results from the prospective PANTHER study with focus on obese patients
2019) In Annals of oncology : official journal of the European Society for Medical Oncology 30(1). p.109-114(
- Contribution to journal › Article
- 2018
-
Mark
A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)
(
- Contribution to journal › Article
- 2017
-
Mark
High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer
(
- Contribution to journal › Article
- 2015
-
Mark
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
(
- Contribution to journal › Article
- 2014
-
Mark
Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events
(
- Contribution to journal › Article
-
Mark
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
(
- Contribution to journal › Article
- 2013
-
Mark
Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel
(
- Contribution to journal › Article
-
Mark
Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial
(
- Contribution to journal › Article
- 2012
-
Mark
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
(
- Contribution to journal › Article